In the Phase 3 REDEFINE 1 trial, cagrilintide monotherapy achieved 11.8% average weight loss over 68 weekscomparable to semaglutide but with a notably lower incidence of nausea and vomiting, making it a potential option for patients who dont tolerate GLP-1 medications well
PubMed, Weiner, Alexandra S., et al
With your thumb and 3rd finger holding the middle of the syringe (similar to holding a pencil or pen but with different fingers) and your index finger on the plunger of the syringe, quickly insert the needle AT A 10-30 DEGREE ANGLE (this way it is impossible to go too deep) until it stops at the hub of the needle/syringe
However, this method may pose risks, including potential side effects and complications associated with injections
Epilepsia 49 , 16511664 (2008)